What is the role of GLP1 analogs in the treatment of obesity?

GLP-1 (glucagon-like peptide 1) analogs play an important role in the treatment of obesity by helping people lose weight and improve their metabolic health.

Some of the most common GLP-1 analogs are:

Liraglutide (Victoza, Saxenda):

Liraglutide is used to treat obesity in adults with a body mass index (BMI) of 30 or greater, or in adults with a BMI of 27 or greater who have at least one weight-related condition, such as type 2 diabetes or high blood pressure. It increases feelings of satiety, reduces appetite and delays gastric emptying, leading to weight loss.

Dulaglutide (Trulicity):

Like liraglutide, dulaglutide is used in the treatment of obesity in adults with a BMI equal to or greater than 30, or in adults with a BMI equal to or greater than 27 who have at least one weight-related comorbidity. Helps reduce appetite and promotes weight loss.

Semaglutide (Ozempic, Wegovy):

Semaglutide is used in the treatment of obesity in adults with a BMI equal to or greater than 30. Like other GLP-1 analogs, it reduces appetite, delays gastric emptying, and promotes weight loss.


These GLP-1 analogs are administered via subcutaneous injections and are typically used as part of a comprehensive approach to obesity treatment, which includes dietary changes, increased physical activity, and lifestyle counseling. In addition to their effect on weight loss, these medications can also improve insulin sensitivity and blood sugar levels, which may be beneficial for people with type 2 diabetes or prediabetes.

It is important to note that the use of GLP-1 analogues should be supervised by a health professional, and the decision to prescribe them should be based on the individual evaluation of each patient, considering their risks and benefits. They may also have side effects, such as nausea and diarrhea, which should be discussed with the doctor.